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Abstract
Aberrant blood vessels enable tumor growth, provide a barrier to immune infiltration, and serve as 
a source of pro-tumorigenic signals. Targeting tumor blood vessels for destruction, or tumor 
vascular disruption therapy, can therefore provide significant therapeutic benefit. Here we describe 
the ability of chimeric antigen receptor (CAR)-bearing T cells to recognize human prostate-
specific membrane antigen (hPSMA) on endothelial targets in vitro as well as in vivo. CAR T cells 
were generated using the anti-PSMA scFv, J591, and the intracellular signaling domains: CD3ζ, 
CD28, and/or CD137/4-1BB. We found that all anti-hPSMA CAR T cells recognized and 
eliminated PSMA+ endothelial targets in vitro, regardless of the signaling domain. T cells bearing 
the 3rd generation anti-hPSMA CAR, P28BBζ, were able to recognize and kill primary human 
endothelial cells isolated from gynecologic cancers. In addition, the P28BBζ CAR T cells 
mediated regression of hPSMA-expressing vascular neoplasms in mice. Finally, in murine models 
of ovarian cancers populated by murine vessels expressing hPSMA, the P28BBζ CAR T cells 
were able to ablate PSMA+ vessels, cause secondary depletion of tumor cells, and reduce tumor 
burden. Taken together, these results provide strong rationale for the use of CAR T cells as agents 
of tumor vascular disruption, specifically those targeting PSMA.
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Introduction
The process of tumor development is intricately linked to changes in the local tumor 
microenvironment. In addition to tumor cells, the microenvironment comprises immune 
cells, fibroblasts, and aberrant tumor blood vessels, as well as non-cellular components such 
as signaling molecules and the extracellular matrix. The relationship of the tumor with the 
microenvironment is dynamic, and cross talk between the two contributes to cancer 
progression. Within the microenvironment, tumor blood vessels play a central role in cancer 
progression, providing both oxygen and nutrient exchange to the tumor (1). In addition, 
endothelial cells lining the blood vessels (i.e., the endothelium) can provide growth signals, 
such as interleukin (IL) 6 (2), which promote tumor cell proliferation. Tumor endothelial 
cells are also able to secrete angiocrine factors that contribute to the stemness of nearby 
cancer cells, promoting both disease severity and resistance to chemotherapy (3). Finally, 
the tumor endothelium provides a physical barrier to immune cell infiltration, actively 
protecting the tumor from immunosurveillance (4, 5). We previously demonstrated that 
activation of endothelin B receptor on the tumor endothelium initiates mechanisms that 
inhibit T-cell adhesion and subsequent tumor penetration (4). In addition, we showed that 
tumor blood vessels up-regulate FasL in response to prostaglandin, vascular endothelial 
growth factor A (VEGF-A), and IL10. FasL expression by the tumor endothelium 
preferentially kills CD8+ T cells while leaving T regulatory cells (Treg) unharmed (5). 
Together these findings emphasize the importance of the tumor vasculature in cancer 
progression and indicate that the destruction of these vessels may have an important impact 
on tumor development.
T cells can be engineered to recognize tumor or tumor vascular-specific antigens through 
transduction with either an exogenous T-cell receptor (TCR) or a chimeric antigen receptor 
(CAR). CARs are composed of a tumor-targeting moiety, most often an scFv, linked to a 
transmembrane region and intracellular signaling domains that activate the T cell upon 
antigen engagement (6). They offer a significant advantage over TCRs in that they are 
MHC-independent (i.e., a single universal receptor can be used to treat all patients whose 
tumor or vasculature expresses the target antigen regardless of their MHC haplotype). 
Several cell-surface targets have been identified to distinguish the tumor endothelium from 
normal vessels. The VEGF receptors (VEGFRs), for example, are highly expressed on the 
vasculature of a broad range of solid tumors (7), and CAR T cells directed against these 
receptors have been shown to destroy the tumor vasculature and impair tumor growth (8,9). 
Although efficacious against these targets in mouse models, CAR T cells have not yet been 
developed against additional tumor vascular antigens.
Prostate-specific membrane antigen (PSMA), best known as a prostate cancer-specific 
target, is a surface glycoprotein abundantly expressed on the endothelium of many solid 
tumors, but not on the normal vasculature (10–11). PSMA is a 750 amino acid type II 
membrane-bound protein transcribed from the PSMA locus, which encodes a number of 
splice variants, including multiple membrane-bound and cytosolic isoforms (12,13). 
Interestingly, the ratio of membrane to cytosolic PSMA dramatically increases in prostate 
cancer (14). Recent studies have demonstrated that PSMA expression confers a proliferative 
advantage to tumor cells through its function as a hydrolase of poly- and gamma-glutamated 
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folate (15). As such, it is presumed that PSMA plays a metabolic role on the activated tumor 
endothelium. Additional functions have also been ascribed to PSMA. For example, mice 
lacking PSMA exhibit impaired angiogenesis as a result of defects in endothelial cell 
invasion (16). The expression of PSMA by the LNCaP prostate cancer cell line has been 
shown to induce the expression and secretion of IL6, which increases the proliferative 
potential of tumor cells (17). Since the tumor endothelium has been shown to be an 
important source of IL6 (2), it is conceivable that PSMA signaling is also involved in the 
production of IL6 from these cells. Taken together, these data implicate PSMA as a 
contributor to tumor progression, and provide strong rationale for the generation of CAR T 
cells against the tumor endothelial cells on which it is expressed.
Here we describe the development of CAR T cell therapy directed against human (h)PSMA 
expressed by the tumor endothelium and provide proof of principle that this approach may 
be used to elicit tumor vascular disruption. We demonstrate that anti-hPSMA CAR-bearing 
T cells function against endothelial targets in vitro regardless of the signaling domain 
incorporated into their design (ζ, 28ζ, BBζ, or 28BBζ). We also establish that the 3rd 
generation CAR T cells, containing the 28BBζ signaling domain, are able to recognize 
primary tumor endothelial cells isolated from subjects with gynecologic cancer. 
Furthermore, we show that in vivo the P28BBζ T cells are able to resolve murine 
hemangioma and hemangiosarcoma tumors, which express hPSMA. Using state of the art 
luciferase imaging technology we show directly, for the first time, that CAR T cells are able 
to eliminate endothelial cells within solid tumors and that vessel destruction results in 
secondary depletion of tumor cells, as well as reduced tumor burden. Overall our work 
demonstrates that PSMA is a valid target for CAR T cell-mediated tumor blood vessel 
destruction, and provides insight into the importance of vascular disruption in the broader 
context of cancer therapeutics.
Materials and Methods
CAR Construction
The J591 (18) and MOv19 (19) scFvs were gifts from M. Sadelain and D. Powell, 
respectively. The pELNS lentiviral vector and the genes encoding the CAR signaling 
domains ζ, 28ζ, BBζ, and 28BBζ were gifts from C. June (20). pELNS is a third generation 
self-inactivating lentiviral expression cassette based on pRRL-SIN-CMV-eGFP-WPRE (21), 
with transgene expression driven by the EF-1α promoter. The constructs were engineered to 
express an upstream eGFP reporter separated from the CAR by a T2A sequence. The J591 
and MOv19 scFvs were amplified via PCR and subcloned into an intermediary vector 
(pCLPS) using 5′ BamHI and 3′ NheI restriction enzyme cut sites. 5′ primer, J591F = 
ATCGggatccGTGCAGCTGCAGCAGTCAGG and 3′ primer, J591R = 
GCTAgctagcCCGTTTCAGGTCCAGCATGG. BamHI and NheI cut sites are underlined, 
respectively. The resulting constructs contained the full-length CAR construct, including 
signaling domain(s). The full-length sequence for each CAR was then isolated from the 
pCLPS vectors using 5′ AvrII and 3′ SalI restriction enzyme cut sites. Finally, the CAR 
constructs were ligated into the pELNS vector backbone, which was gel-purified after 
digestion with XbaI (compatible with AvrII) and SalI restriction enzymes.
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Lentiviral production
Lentivirus was generated as previously described (22). Briefly, 2.0×106 293T cells were 
plated in T-150 tissue culture flask 18 h before transfection with transgene (15 μg, pELNS) 
and packaging plasmids (7 μg pVSV-G, 18 μg pRSV-REV, and 18 μg pMDLg/p.RRE). 
Supernatants were collected at 24 and 48 h and were then combined and concentrated via 
ultracentrifugation at 28,000 RPM for 3 h. Virus was re-suspended in 2 mL RPMI (10% 
FBS, 100 IU mL−1 penicillin, and 100 μg mL−1 streptomycin sulfate), flash frozen, and 
stored at –80° until needed.
Human T-cell transduction
T cells were isolated from healthy donors by the Human Immunology Core at the University 
of Pennsylvania under a protocol approved by the University Institutional Review Board. 
With minor modifications, T cells were transduced as previously described (22). Briefly, T 
cells were cultured in RPMI supplemented with 10% FBS, 100 IU mL−1 penicillin, and 100 
μg mL−1 streptomycin sulfate. 20 h prior to transduction, 5.0×105 T cells were activated 
using anti-CD3/anti-CD28 coated beads (Invitrogen, Carlsbad, CA) at a 2:1 bead to T cell 
ratio in RPMI supplemented with 50 IU mL−1 recombinant human IL2 (Peprotech, Rocky 
Hill, NJ). Activated T cells were spinoculated at 1000 g for 90 min with lentivirus 
[multiplicity of infection (MOI) of 10] and polybrene (8 μg mL−1; Sigma-Aldrich, St. Louis, 
MO) in a total volume of 1 mL. 24 h after spinoculation, half the media was removed (0.5 
mL) and cells were given 1.5 mL of fresh RPMI with 50 IU mL−1 recombinant human IL2. 
The media was replenished every other day with fresh RPMI and IL2 (50 IU mL−1) so that 
T-cell density did not exceed ~1.0×106 mL−1. The T cells were used between 14–28 d after 
transduction.
Cell Lines
Low-passage (P16) 293T cells purchased from the American Type Culture Collection 
(ATCC, Manassas, VA) were used for the production of lentivirus particles. The MS1 
(mouse pancreatic islet) endothelial cell line was also purchased from the ATCC. 
Immortalized H5V (mouse heart endothelial cells) were previously acquired (23). 293T, 
MS1, and H5V cell lines were grown in RPMI supplemented with 10% FBS, 100 IU mL−1 
penicillin, and 100 μg mL−1 streptomycin sulfate. HMEC-1 cells, an SV40 transformed 
human microvascular endothelial cell line (24), were obtained from the Centers for Disease 
Control and Prevention (Atlanta, GA) and grown in MCDB 131 media (Invitrogen, 
Carlsbad, CA) containing mouse EGF (BD, Franklin Lakes, NJ), hydrocortisone (Sigma-
Aldrich, St. Louis, MO), 10% FBS, 100 IU mL−1 penicillin, and 100 μg mL−1 streptomycin 
sulfate and 1x GlutaMax (Invitrogen, Carlsbad, CA). All cell lines used were tested by the 
University of Pennsylvania Cell Center (Philadelphia, PA) and found to be mycoplasma-
free. No other authentication assay was performed.
Cell Line transduction
Stable expression of luciferase was accomplished by lentiviral transduction of the MS1, 
H5V, and HMEC-1 cell lines. 2.5×105 endothelial cells were placed in a 6-well plate and 
virus containing the gene for either firefly luciferase or renilla luciferase was added at an 
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MOI of 10. Media was changed 24 h after transduction. Cells were sorted for either firefly 
or renilla luciferase based upon reporter expression of the red fluorescent protein, mCherry, 
(RFP) or the enhanced green fluorescent protein (eGFP), respectively, using a MOFLO cell 
sorter (Cytomation). Subsequent splits from the luciferase+ lines were then transduced with 
human PSMA as described above.
Flow Cytometry
CAR T cells were identified primarily through detection of their eGFP reporter. For surface 
detection, T cells were stained with an APC-conjugated goat anti-mouse F(ab2) fragment 
(Jackson, West Grove, PA; #115-136-072). Bcl-xL expression was detected using a mouse 
anti-human Bcl-xL Ab (SouthernBiotech, Birmingham, AL; clone 7B2.5) after fixation and 
permeabilization with an intracellular staining kit (eBioscience, San Diego, CA). PSMA was 
detected using a humanized J591 mAb (gift from N. Bander) and an APC-conjugated anti-
human secondary Ab (Jackson, West Grove, PA; #109-136-098). Positive staining was 
assessed by comparison with a human IgG isotype control Ab (Enzo, Farmingdale, NY; 
#ALX-804-133-C100). In addition to the J591 mAb, human tumor digests were stained with 
APC-Cy7-conjugated anti-human CD45 (BD, Franklin Lakes, NJ; clone 2D1), Pacific-Blue-
conjugated anti-human CD31 (BioLegend, San Diego, CA; clone WM59), and PE-
conjugated anti-folate receptor (R&D, Minneapolis, MN; clone 548908) Abs prior to 
analysis. Harvested mouse tumors were also stained with the J591 mAb, as well as APC-
Cy7-conjugated anti-human CD45 (BD, Franklin Lakes, NJ; clone 2D1) and Pacific-Blue-
conjugated anti-mouse CD31 (BioLegend, San Diego, CA; clone 390) Abs. All samples 
were stained with the fixable viability dye eFlour 506 prior to analysis (eBioscience, San 
Diego, CA).
T cell proliferation studies
Prior to co-culture with target cell lines, T cells were labeled with CellVue® Claret as 
described in the kit’s technical bulletin (Sigma-Aldrich, St. Louis, MO). Labeling was 
confirmed by flow cytometry prior to co-culture. 1.0×105 CAR T cells were then cultured 
with 5.0×104 HMEC-1 or HMEC-1PSMA at an effector to target (E:T) ratio of 2:1 for 5 days 
in 48-well flat-bottom plates. Flow cytometry was used to analyze the intensity of CellVue® 
staining after co-culture. CAR+ T cells were identified by eGFP expression. To quantify the 
membrane staining between the T cells cultured with the HMEC-1 versus HMEC-1PSMA, 
the geometric mean fluorescence intensity (MFI) of Cellvue® Claret staining was measured 
for the CAR-positive T cells. To normalize across multiple donors, the MFI of CellVue® 
staining on CAR+ T cells after co-culture with HMEC-1PSMA was divided by the MFI of the 
CAR+ T cells after co-culture with the HMEC-1.
Cytokine Release Assays
IFNγ ELISAs were performed as directed in the Human IFNγ ELISA MAX technical 
manual (BioLegend, San Diego, CA). For cell line assays, 7.5×104 CAR T cells were 
cultured overnight with 2.5×104 endothelial targets (E:T = 3:1). Triplicate cultures were 
performed in 96-well flat-bottom plates. Supernatants were collected from each well after 18 
h. For assays utilizing primary human tumor samples, 9.0×104 CAR T cells were cultured 
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overnight with 3.0×104 enriched endothelial targets (E:T = 3:1). Cultures were performed in 
96-well flat-bottom plates and supernatants were collected after 18 h.
Cytotoxicity Assays
51Cr release assays were performed as previously described (22). CAR T cells were cultured 
for 18 h with endothelial targets at E:T ratios of 10:1, 3:1, and 1:1. Specific lysis was 
calculated as (experimental – spontaneous lysis/maximal – spontaneous lysis) × 100. 
Luciferase based assays were performed similarly; CAR T cells were co-cultured for 18 h 
with endothelial targets engineered to express either firefly or renilla luciferase at the ratios 
indicated in the figure legend(s). Co-cultures were performed in triplicate using opaque 96-
well flat-bottom plates in phenol-free RPMI. Single luciferase assay (firefly) measurements 
were taken according to Luc-Screen® technical manual (Life Technologies, Grand Island, 
NY), whereas dual luciferase assay (firefly and renilla) measurements were made as directed 
by the Dual-Glo® technical manual (Promega, Madison, WI). The percentage of specific 
lysis was calculated as 100 – (luciferase signal treated/luciferase signal untreated × 100). For 
the bystander killing assays, the number of CAR T cells, as well as the number of antigen 
negative target cells, remained constant for all ratios (5.0×104). PSMA positive targets were 
added at the ratios described in the figure legend(s).
Time-lapse microscopy
24-well flat-bottom plates were coated with a thin layer (300 μL per well) of Matrigel (BD, 
Franklin Lakes, NJ) and allowed to solidify at 37° C for 30 min. Next, either 1.0×105 
HMEC-1 or 1.0×105 HMEC-1PSMA endothelial cells were seeded into the wells. 
Microvessels were given 8 h to form prior to addition of the CAR T cells. After 8 h, 3.0×105 
CAR T cells were added to each well and images were taken at 0, 24, and 48 h after 
initiation of the co-culture (E:T = 3:1). Cells were kept in an environmentally controlled 
chamber at 37° C with 5% CO2 throughout the experiment. X-Y coordinates were saved for 
each well so that the identical field of view could be captured at each time point. Pictures 
were taken using a fluorescence microscope (ECLIPSE Ti; Nikon Corporation, Tokyo, 
Japan) equipped with a charge-coupled device camera (Photometrics CoolSnap HQ2; Roper 
Industries, Inc, Sarasota, FL, USA) and NIS-Elements AR software (v 3.2; Nikon 
Corporation).
Immunohistochemistry
For human tissue microarray (TMA) staining, paraffin-embedded tissues were baked at 60 
°C for 1 h, deparrafinized in xylenes, rehydrated in sequential gradations of alcohol, and 
washed in water. Depending on the Ab, antigen retrieval was performed using either citrate 
or EDTA buffer. Endogenous peroxidase was inactivated with Dual Endogenous Enzyme 
block (Dako, Carpnteria, CA). Following Ab staining, TMAs were visualized with 
diaminobenzidine tetrahydrochloride (Dako, Carpnteria, CA) or an alkaline phosphatase red 
substrate kit (dual stains). Sections were then counterstained with hematoxylin. Sections 
were stained with an anti-human PSMA Ab (Dako, Carpnteria, CA; clone 3E6) alone, or in 
combination with anti-human CD34 Ab (Thermo Scientific, Waltham, MA; rabbit 
polyclonal). The TMAs were then scanned and analyzed using ImageScope software. For 
TMAs that included multiple cores from the same subject, individuals were considered 
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PSMA+ if staining could be confirmed on any of the cores from that subject. Damaged or 
absent cores were excluded from analysis.
Enrichment of human CD31+ endothelial cells
Human tumor specimens were gathered with approval from the University of Pennsylvania 
institutional review board in compliance with the US Health Insurance Portability and 
Accountability Act (HIPAA). Briefly, tumors were mechanically or enzymatically digested 
to yield single-cell suspensions that were subsequently frozen and stored at –150° C until 
needed. Samples were rapidly thawed in a 37° C water bath. Viable cells were counted using 
Trypan Blue. Tumor digests were first depleted for CD45 using Miltenyi anti-human CD45 
beads, as per manufacturer’s instructions (Miltenyi, San Diego, CA). The CD45− fraction 
was then enriched for human CD31 endothelial cells using Miltenyi anti-human CD31 beads 
(Miltenyi, San Diego, CA). Both the CD45−CD31− and CD45−CD31+ population were 
retrieved and analyzed by flow cytometry and/or used in functional assays.
Mice
All protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee at the University of Pennsylvania. All experiments were done using female 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (aged 8–10 weeks) purchased from and 
housed at the Stem Cell Xenograft Core (SCXC), a germ-free facility at University of 
Pennsylvania.
In vivo assays with HMEC-1 cells
Matrigel plugs containing HMEC-1 (left flank) and HMEC- 1PSMA (right flank) endothelial 
cells were injected s.c. into the flanks of mice. CAR-positive T cells were administered via 
tail vein injection immediately following implantation of the plugs. The number of cells 
inoculated/injected is noted in the figure legend(s). Mice were sacrificed after 11 days and 
the Matrigel plugs retrieved and digested with 3U mL−1 dispase (Sigma-Aldrich, St. Louis, 
MO) and 25 μg mL−1 DNase to yield single-cell suspensions. The cells collected from the 
plugs, as well as splenocytes collected from the sacrificed animals, were then stained and 
analyzed by flow cytometry.
In vivo assays with MS-1 cells
Mice were injected s.c. on each flank with MS1 (left flank) and MS1PSMA (right flank) 
endothelial cells and CAR-bearing T cells were administered as noted in the figure 
legend(s). Hemangioma development and response to treatment was monitored twice a week 
by measuring luciferase luminescence. Mice were injected intraperitoneally with 100 μL of 
D-Luciferin stock solution (30 mg mL−1, GoldBio, St. Louis, MO), anesthetized using 
isofluorane, and imaged 20 min after luciferin injection. To avoid bias, the PSMA+ tumor 
(right flank) was measured first. Mice were then flipped, and the antigen-negative tumor 
(left flank) was analyzed, typically 1–2 minutes after the right flank. Data were gathered 
using a Xenogen IVIS imaging system, and analyzed using Living Image software 
(PerkinElmer, Waltham, MA). When palpable, tumors were measured with Vernier calipers 
and volumes were calculated using the equation .
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In vivo assays with H5V cells
Mice were injected i.v. with H5VPSMA endothelial cells and CAR T cells were administered 
as noted in the figure legend(s). Tumor development and response to treatment was 
monitored twice a week by measuring luciferase luminescence. Mice were injected with 
luciferin as described above, and 20 min after injection the ventral surface of the animals 
was imaged. Mice were weighed twice per week and sacrificed if/when they lost more than 
10% of their initial body mass.
In vivo assays with MS1/ID8 cells
Mice were injected s.c. on each flank with MS1/ID8 (left flank) and MS1PSMA/ID8 (right 
flank) cells and CAR T cells were administered as noted in the figure legend(s). Luciferase 
luminescence and tumor volume were measured as described for the MS1 tumors. After 
termination of the MS1/ID8VEGF experiment, the remaining tumors were excised and split 
for analysis. Half of each tumor was embedded and frozen in Tissue-Tek® optimum cutting 
temperature medium (VWR, Philadelphia, PA), while the other half was digested overnight 
in serum-free RPMI containing collagenase (175 collagen digestion units mL−1) and DNAse 
(20 Kunitz units mL−1). After digestion, tumors were filtered through a 70 μm mesh filter 
and treated with Ammonium-Chloride-Potassium buffer to lyse red blood cells. Digests 
were then analyzed by flow cytometry. Tumors not large enough to be split were embedded 
in O.C.T. and frozen. For the ID8VEGF, MS1/ID8VEGF, MS1PSMA/ID8VEGF control mice 
(Fig. 5), eGFP radiance was also measured. The ID8VEGF tumor cells brightly express an 
eGFP reporter (data not shown). Spectral unmixing for eGFP was performed using the 
Living Image software, and the results were plotted against luciferase luminescence values 
taken concurrently (Fig. 5F–J).
Statistical Analysis
Values are expressed as the mean ± either SD or SEM, as indicated in the figure legends. 
Statistical differences were determined to be significant at P < 0.05. Specific tests used are 
described in the figure legends. All analyses were performed using Graphpad Prism 
Software.
Results
Design and characterization of an anti-vascular CAR targeting endothelial PSMA
The effector function and persistence of CAR-bearing T cells is dependent upon the 
signaling domains incorporated in their design. Costimulation through CD28 and/or 4-1BB 
augments CAR T-cell function in vivo, generating a more potent antitumor response (18,20). 
In vitro, the impact of costimulation is less clear with studies reporting either no difference 
in the cytolytic potential of the different generation CAR T cells (20) or enhanced killing 
using the 2nd and 3rd generation CAR T cells (18). These data suggest that the intrinsic 
properties of the targeted cell line(s) may influence the functionality of the various CAR T 
cells, and that costimulation may confer a greater advantage against certain cell types or cell 
lines. Since the effect of costimulation on CAR T-cell function has not been ascertained for 
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endothelial targets, we designed a series of CAR constructs containing the ζ, 28ζ, BBζ, or 
28BBζ signaling domains and compared their functionality against endothelial cells in vitro.
Research from the laboratory of Michel Sadelain has shown that CAR T cells targeted 
against hPSMA (hereafter referred to as PSMA) are able to eliminate prostate cancer cells in 
vitro as well as in vivo (18). The scFv utilized in these constructs was derived from the 
mouse monoclonal (m)Ab J591, which was also used to identify PSMA on blood vessels 
within a number of solid tumors (10,11,25). We therefore utilized the J591 scFv in the 
design of our CAR constructs, which we referred to as Pζ, P28ζ, PBBζ, and P28BBζ, based 
upon the intracellular signaling domain incorporated into their design. In addition, we also 
utilized a specificity control CAR, FR28BBζ, which recognizes the non-vascular antigen, 
human folate receptor alpha (FRα) (19). Each CAR was subcloned downstream of an eGFP 
reporter within the pELNS lentiviral cassette (Fig. 1A,B). Typical transduction efficiencies 
ranged from 50–90% in primary human T cells (Fig. 1C). To confirm CAR surface 
expression, the P28BBζ T cells were stained with a goat anti-mouse F(ab)2 fragment. eGFP 
expression and CAR surface detection were strongly correlated, validating the use of the 
eGFP reporter as a proxy for CAR expression (Supplementary Fig. S1).
Although PSMA has been detected on the tumor endothelium in vivo, it has not been 
described on endothelial cells in culture. To ascertain whether cultured human endothelial 
cells express PSMA, we stained both the immortalized HMEC-1 cell line (24) as well as 
primary human umbilical vein endothelial cells (HUVEC), using the J591 mAb. We were 
unable to detect PSMA on either the HMEC-1 (Fig. 1D) or the HUVEC (not shown). We 
therefore engineered the HMEC-1 cells to express PSMA using lentivirus (Fig. 1D). To 
compare the ability of each CAR construct to redirect T cells towards endothelial PSMA, we 
first measured the proliferative capacity of the CAR-bearing T cells in response to the 
HMEC-1PSMA cell line. All anti-PSMA CAR T cells proliferated in response to the 
HMEC-1PSMA regardless of their signaling domain (Fig. 1E,F), but did not proliferate in 
response to the antigen negative HMEC-1 (not shown). There were no statistical differences 
between the groups. In contrast to the anti-PSMA T cells, control FR28BBζ CAR T cells did 
not show any significant proliferation in response to the HMEC-1PSMA when compared to 
untransduced (UNTR) T cells (Fig. 1F). Similarly, we observed that all the anti-PSMA CAR 
T cells were able to specifically kill the HMEC-1PSMA during overnight co-culture, with no 
statistically significant differences detected between the anti-PSMA T cells (Fig. 1G). 
Finally, we compared the ability of each CAR to confer resistance to apoptosis by measuring 
the anti-apoptotic factor, Bcl-xL, following activation. After co-culture with the 
HMEC-1PSMA, the P28BBζ T cells induced the highest levels of Bcl-xL expression, 
although this observation did not reach statistical significance (Supplementary Fig. S2A,B). 
These data demonstrate that, in vitro, all CAR constructs are able to react against endothelial 
targets regardless of their intracellular signaling domain. Since we found no advantage to 
using any of the examined signaling domains in vitro, and since the third generation CAR T 
cells (28BBζ) were found to be equivalent or superior to either the 1st (ζ) or 2nd (28ζ or BBζ) 
generation CAR T cells in the context of tumor control in vivo (18), we selected the P28BBζ 
T cells for further experimentation.
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PSMA is expressed on the vasculature of primary and metastatic cancer
PSMA has been detected on tumor blood vessels in a variety of cancers, including ovarian 
(26) (summarized in Supplementary Fig S3a). To confirm this observation for individuals 
with ovarian cancer, we performed immunohistochemistry on a TMA composed of 13 
primary ovarian cancer specimens and 15 matched metastases (Fig. 2A, top row). We 
observed PSMA expression on vessel-like structures within the majority of tumors, with 
12/13 (85%) of the subjects expressing PSMA within their primary ovarian lesion(s), and 
14/15 (93%) expressing PSMA on one or more of their metastases (Fig. 2B). We did not 
identify PSMA on any of the 16 normal ovary cores analyzed. Endothelial expression of 
PSMA was confirmed by co-staining of the TMA using a CD34 antibody, in addition to the 
anti-PSMA antibody (Fig. 2A, bottom row). Here we noticed the presence of CD34+PSMA− 
vessels in some of the cores analyzed (Fig. 2C), corroborating the observations made in 
other cancers that PSMA expression was heterogeneous on vessels within the tumor 
(Supplementary Fig. S3B). To define the percentage of endothelial cells expressing PSMA 
within the tumor, we examined freshly dissociated cancer samples by flow cytometry. In 
support of our observations by IHC, we found PSMA expression on approximately 40–60% 
of the CD45−CD31+ endothelial cells (Fig. 2D).
Next we asked whether the P28BBζ CAR T cells were capable of recognizing and killing 
tumor endothelial cells isolated from individuals with cancer. Tumor endothelial cells were 
enriched from freshly dissociated tumor samples first by negative selection of CD45+ 
leukocytes and then by positive selection of CD31+ endothelial cells using magnetic bead 
sorting. CD31-enriched and CD31-depleted tumor-derived cells were then incubated with 
P28BBζ CAR T cells for 18 h. We found that P28BBζ CAR T cells substantially reduced the 
percentage of PSMA+ endothelial (CD45−CD31+) cells in primary tumor-derived cells. The 
control FR28BBζ CAR T cells had no impact on the percentage of PSMA+ cells remaining 
in the culture (Fig. 2E). To confirm the activation of the P28BBζ CAR T cells in these 
cultures, we performed IFNγ ELISA on the supernatants collected from the overnight co-
cultures of the P28BBζ CAR T cells with either the CD31-enriched or the CD31-depleted 
populations. IFNγ was produced in all instances in which the P28BBζ T cells were co-
cultured with the CD31-enriched endothelial cells (Fig. 2F). Interestingly, we also observed 
IFNγ production in one of the CD31-depleted co-cultures (Fig. 2F, #1913). To determine 
whether expression of PSMA by the tumor cells could explain this observation, we stained 
the CD45−CD31− population for PSMA as well as FRα, a tumor-specific antigen in ovarian 
cancer (27). For subject #1913, we found that a substantial portion of the FRα+ cells stained 
positive for PSMA (Supplementary Fig. S3C). Because the main cell populations in the 
CD45−CD31− fraction are tumor cells and stroma fibroblasts, and because the stroma of 
gynecologic cancers does not express the FRα (28,29), these findings suggest that tumor 
cells in some individuals with ovarian cancer may also express PSMA, which has been 
noted for other cancers (30). Collectively, our data along with those in numerous published 
reports (Supplementary Fig. S3A) demonstrate that PSMA is expressed widely on the tumor 
vasculature and provide rationale for the development of CAR T-cell therapy against this 
antigen.
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P28BBζ CAR T cells target human tumor vasculature expressing PSMA
To simulate the interactions of P28BBζ CAR T cells with human tumor blood vessels in 
vitro, we plated HMEC-1 or HMEC-1PSMA endothelial cells on Matrigel basement 
membranes and allowed the cells to self-assemble into microvessels (8 h). Upon assembly, T 
cells were added, and the cultures were monitored for 48 h by fluorescence microscopy (Fig. 
3A). As early as 24 h after addition of the T cells to the microvessels, we observed specific 
localization of the P28BBζ CAR T cells with the HMEC-1PSMA microvessels, and within 48 
h the HMEC-1PSMA vessels were destroyed (Fig. 3B). In contrast, the antigen-negative 
microvessels persisted throughout the duration of the co-culture with the P28BBζ CAR T 
cells. As expected, the T cells directed against FRα did not impact the persistence of either 
the HMEC-1 or HMEC-1PSMA microvessels (Fig. 3A). These data indicate that the P28BBζ 
CAR T cells were able to specifically recognize PSMA+ vessels, but not normal (PSMA−) 
vascular structures in vitro.
We next assessed the ability of the P28BBζ CAR T cells to recognize human endothelial 
cells expressing PSMA in vivo. We transplanted Matrigel plugs containing either HMEC-1 
(left flank) or HMEC-1PSMA (right flank) cells into severely immunodeficient NSG mice 
(Fig. 3C). Immediately after transplantation of the Matrigel plugs, mice were given an 
intravenous (i.v.) injection of either P28BBζ CAR T cells or control FR28BBζ CAR T cells. 
The plugs and spleens were harvested 11 days after inoculation and analyzed for the 
presence of CAR-positive T cells via flow cytometry. In mice receiving the P28BBζ T cells, 
we found large numbers of CAR T cells in the plugs harboring the HMEC-1PSMA cells, 
whereas the plugs containing control HMEC-1 cells were largely devoid of T cells (Fig. 
3D,E). Similarly, very few FR28BBζ control T cells were found in the plugs containing 
either the PSMA positive or negative endothelial cell lines. Finally, we measured the 
percentage of CAR T cells found in the spleens of the treated mice and found significantly 
more P28BBζ CAR T cells when compared to mice that received the FR28BBζ control T 
cells (Fig. 3E). Together, these data demonstrate that the P28BBζ CAR T cells are able to 
recognize and accumulate on PSMA+ endothelial cells and that they are able to persist in 
vivo in the presence of the antigen.
P28BBζ CAR T cells eliminate PSMA+ vascular neoplasms
Because the HMEC-1 model did not reproducibly form vascular structures in vivo, we used 
two well-established murine endothelial models, the MS1 murine hemangioma model (31) 
and the H5V hemangiosarcoma model (23), to test the therapeutic efficacy of the P28BBζ 
CAR T cells. First, we engineered the expression of human PSMA onto the surface of the 
MS1 and H5V endothelial cell lines (Fig. 4A). To assess the specificity and ability of the 
P28BBζ T cells to react against these endothelial targets, we performed an IFNγ ELISA on 
supernatants collected from overnight co-cultures of the P28BBζ T cells with the PSMA-
negative endothelial cell lines (MS1 and H5V) and their PSMA-transduced counterparts 
(MS1PSMA and H5VPSMA). We found that IFNγ production was limited to the cultures 
containing the P28BBζ CAR T cells and PSMA+ endothelial cells (Fig. 4B). Next, we asked 
whether the P28BBζ CAR T cells would be able to specifically kill the PSMA+ endothelial 
cells. Using a chromium release assay, we found that the P28BBζ CAR T cells killed the 
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majority of the PSMA+ endothelial cells within 18 h of co-culture, while the PSMA− cell 
lines were spared (Fig. 4C).
Next, we injected NSG mice subcutaneously (s.c.) with MS1 cells (left flank) and MS1PSMA 
cells (right flank), both of which had been previously engineered to express firefly luciferase 
to allow us to make non-invasive, real time tumor measurements throughout tumor 
progression and treatment. The hemangioma lesions were allowed to develop and tumor 
growth was monitored via luciferase luminescence. Mice were treated with a single i.v. 
administration of 5.0×106 CAR T cells 24 days after tumor inoculation (Fig. 4D). In mice 
receiving the P28BBζ CAR T cells, we observed rapid regression of the MS1PSMA 
hemangiomas, whereas the antigen-negative MS1 flank was unaffected (Fig. 4E). 
Macroscopic examination of the hemangiomas upon sacrifice revealed that injection of the 
P28BBζ CAR T cells led to complete regression of the PSMA+ tumors (Fig. 4F). In contrast, 
the control FR28BBζ CAR T cells had no impact on either of the hemangiomas. We also 
tested the P28BBζ T cells against larger, more developed, MS1 and MS1PSMA hemangiomas 
(Supplementary Fig. S4A). Again, we observed rapid regression of the MS1PSMA tumors 
after administration of the P28BBζ CAR T cells, as measured by both luciferase 
luminescence and caliper measurement (Supplementary Fig. S4B), which we confirmed 
visually upon sacrifice of the mice (Supplementary Fig. S4C). Importantly, in both treatment 
models the P28BBζ CAR T cells demonstrated specificity and reactivity exclusively against 
the PSMA+ tumors.
Finally, we assessed the ability of the P28BBζ CAR T cells to treat murine H5V 
hemangiosarcoma, an aggressive vascular target that metastasizes to the lung. Twenty-one 
days following i.v. inoculation with H5VPSMA endothelial cells, NSG mice were given three 
i.v. injections of 5.0×106 CAR T cells 72 h apart (Fig. 4G). We monitored the progression 
and response of the tumors to treatment by luciferase luminescence, and mice were 
sacrificed upon losing 10% of their initial body mass. By the third injection of CAR T cells, 
the H5VPSMA cells were nearly undetectable in the P28BBζ CAR treatment group, whereas 
no effect was seen in the FR28BBζ CAR treatment group (Fig. 4H,I). Furthermore, mice 
treated with the P28BBζ CAR T cells lived significantly longer than those treated with PBS 
or FR28BBζ T cells (Fig. 4J). Collectively, results from these models demonstrate that the 
P28BBζ CAR T cells are able to traffic to and eliminate aberrant PSMA+ tumor vessels in 
vivo, and that PSMA-targeting CAR T cells are potent mediators of tumor vascular 
disruption.
CAR T cells ablate PSMA+ vasculature in solid tumors
Elimination of tumor vessels by vascular disrupting agents can cause regression of solid 
tumors (32). To test whether the P28BBζ CAR T cells could also elicit this effect, we 
employed a pair of syngeneic vasculature/tumor chimeric transplant models. MS1 
endothelial cells have been co-injected with both murine (ID8) and human (2008) tumor 
cells, and were found to form functional vessels within both models, as assessed by 
immunohistochemistry and hemoglobin content (33–35). We therefore interrogated the 
impact of P28BBζ-mediated vessel destruction in the MS1/ID8 tumor model, as well as in 
the MS1/ID8VEGF tumor model, in which the ID8 tumor cells were engineered to 
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overexpress mouse VEGF164 (36). The endothelial and tumor cells were combined at an 
optimal ratio, such that the majority of tumor blood vessels would be derived from the 
MS1/MS1PSMA endothelial cells. Fig. 5A illustrates a representative experiment where mice 
were inoculated with ID8VEGF, MS1/ID8VEGF, or MS1PSMA/ID8VEGF tumors. By day 41, 
the majority of the CD31+ endothelial cells from the ID8VEGF/MS1PSMA tumors were found 
to express PSMA by immunofluorescence microscopy and exhibit typical vessel 
morphology, confirming that the exogenous MS1 endothelial cells were substantially 
contributing to the tumor vasculature in this model (Fig. 5B). These results were verified by 
flow cytometry, which showed that more than 65% of CD31+ endothelial cells purified from 
the tumors were PSMA+ (Fig. 5C). Importantly, the CD31+ endothelial cells contributed less 
than 2% to the total cells isolated from the chimeric tumors, which was similar to what was 
observed for the ID8VEGF-only tumors, in which the vasculature was derived from 
endogenous endothelial cells. Therefore, we concluded that the majority of the tumor was 
derived from the ID8VEGF cells or stromal cells and not the co-injected MS1 endothelial 
cells (Fig. 5D). In addition, we noted no difference in the tumor growth kinetic between the 
ID8VEGF alone tumors or the ID8VEGF tumors augmented with MS1 or MS1PSMA cells (Fig. 
5E), further demonstrating that the chimeric tumors reproduced a “normal” tumor growth 
condition, and confirming that the addition of MS1 or MS1PSMA cells did not substantially 
contribute to the volume of these tumors.
We next asked whether the proportion of MS1-derived vessels was consistent throughout 
tumor development. For these experiments we used MS1 and MS1PSMA cells engineered to 
express firefly luciferase and ID8VEGF tumor cells engineered to express eGFP. In mice 
injected with either MS1/ID8VEGF or MS1PSMA/ID8VEGF tumors, we compared seven 
longitudinal luciferase luminescence measurements, obtained between days 17 and 41, to 
seven longitudinal eGFP radiant efficiency measurements obtained at the same time points 
(Fig. 5F–J). We performed linear regression analyses on the values obtained and found that 
endothelial luminescence was strongly correlated with tumor radiant efficiency (Fig. 5F–J), 
indicating that the exogenous endothelial cells expanded proportionally to the tumor cells. 
Thus, we concluded that within this tumor model the exogenous endothelial cells provide 
the main source of tumor endothelial cells required for neovascular formation and that the 
contribution of MS1 endothelial cells was consistent throughout tumor development, 
beginning as early as 17 days after tumor inoculation. Overall, our data indicate that the 
presence of the MS1 or MS1PSMA vessels largely obviates the need for endogenous 
endothelial cell recruitment, and that the MS1 endothelial cells do not constitute a 
significant portion of the cells within the tumor, supporting the assertion that the MS1 cells 
are predominantly forming tumor blood vessels and not contributing substantially to the 
overall tumor mass. Finally, we have demonstrated that the MS1 and MS1PSMA endothelial 
cells can be followed non-invasively during tumor growth within this model, allowing for 
their persistence or elimination to be monitored after treatment with CAR T cells.
To test the ability of P28BBζ CAR T cells to ablate tumor vasculature in vivo, we first 
utilized the MS1/ID8 tumor model. NSG mice were injected with MS1/ID8 (left flank) and 
MS1PSMA/ID8 (right flank) tumors, which were allowed to develop for 81 days before 
treatment with a single injection of 1.0×107 CAR T cells (Supplementary Fig. 5A). We 
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found that the P28BBζ CAR T cells were able to eliminate the MS1PSMA endothelial cells 
quickly, as indicated by luciferase luminescence measurements (Supplementary Fig. 5B, 
lower panel). In contrast, vessels within the MS1/ID8 tumors were unaffected by the 
P28BBζ CAR T cells (Supplementary Fig. 5B, upper panel). Administration of the 
FR28BBζ CAR T cells had no impact on the tumor blood vessels, confirming the specificity 
of the P28BBζ T cells.
Since VEGF plays an important role in the development and stabilization of new tumor 
vessels, and has been implicated in tumor resistance to pharmacologic vascular disruption 
agents (VDAs) (37), we next sought to evaluate the in vivo impact of the P28BBζ CAR T 
cells on the vasculature of solid tumors expressing high levels of VEGF-A using the 
ID8VEGF model (36). The MS1/ID8VEGF tumors grew more rapidly than the MS1/ID8 
tumors, necessitating that those mice be sacrificed within approximately 40 days to avoid 
ulceration. Mice were therefore treated earlier and with three injections of 5.0×106 CAR T 
cells, beginning 25 days after tumor inoculation (Fig. 6A). P28BBζ CAR T cells induced 
rapid regression of the PSMA+ MS1 endothelial cells but had no effect on the control MS1 
cells (Fig. 6B). In addition, the control FR28BBζ CAR T cells had no impact on the blood 
vessels of either tumor. Upon sacrifice we collected and enzymatically dissociated all 
tumors, which were subsequently stained using antibodies for CD31 and PSMA and 
analyzed via flow cytometry. No CD31+PSMA+ endothelial cells were found within the 
tumors of the P28BBζ-treated mice. In control treated mice, between 60–80% of the CD31+ 
endothelial cells were PSMA+ within the MS1PSMA/ID8VEGF tumors (Fig. 6C). Following 
successful treatment, CD31+ endothelial cells accounted for less than 0.5% of the total live 
cells isolated from the tumors, which was lower than either the untreated tumors or tumors 
treated with control FR28BBζ CAR T cells (Fig. 6D). These findings indicate that, similar to 
VDAs, CAR T cells can trigger regression of established tumor vasculature.
CAR T cells induce secondary loss of tumor cells and regression of solid tumors
To assess whether vascular disruption was causing secondary loss of tumor cells, we 
examined the effects of P28BBζ CAR T cells on tumor growth in the experiments described 
above. In the MS1/ID8 model (outlined in Supplementary Fig. 5A), treatment with P28BBζ 
CAR T cells led to a significant decrease in the overall size of the MS1PSMA/ID8 tumors, 
but not of the antigen-negative MS1/ID8 tumors (Supplementary Fig. 5C). In addition, 
growth of MS1PSMA/ID8VEGF tumors was significantly impaired in P28BBζ-treated mice 
(Supplementary Fig. 6A,B). This response was dose-sensitive, as mice treated with a single 
injection of 1×107 CAR T cells did not eliminate PSMA+ endothelial cells as rapidly and did 
not inhibit the growth of ID8VEGF tumors as effectively as mice treated with three injections 
of 5×107 CAR T cells. These data demonstrate that even in the context of VEGF 
overexpression, elimination of the antigen-positive vasculature by CAR T cells can lead to 
significant tumor regression.
Given that endothelial cells account for less than 2% of the cells found within the MS1/
ID8VEGF and MS1PSMA/ID8VEGF tumors (see Fig. 5D), we hypothesized that the regression 
observed in the P28BBζ-treated mice was not merely reflecting the loss of MS1PSMA cells 
from the ID8VEGF tumors, but rather indicating a significant loss of tumor cells in response 
Santoro et al. Page 14
Cancer Immunol Res. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
to T cell-mediated vascular disruption. To ascertain whether this was true, we developed an 
ID8VEGF model in which the tumor cells expressed firefly luciferase and the MS1 cells did 
not. As before, NSG mice were inoculated with MS1/ID8VEGF (left flank) and 
MS1PSMA/ID8VEGF (right flank) tumors. Three administrations of 5.0×107 CAR T cells 
were given, beginning on day 22 (Fig. 7A). Both luciferase luminescence and tumor volume 
measurements revealed that treatment with P28BBζ T cells impaired tumor growth (Fig. 
7B). To determine if the P28BBζ T cells were mediating tumor cell destruction, we 
compared the fold-change in tumor cell luminescence from mice receiving the P28BBζ T 
cells. We observed a significant decrease in tumor luminescence from the MS1PSMA/
ID8VEGF tumors after the second injection of P28BBζ T cells, between days 24 and 28 (Fig. 
7C). In contrast, we observed a significant increase in signal from the antigen negative 
MS1/ID8VEGF tumors during that same period (Fig. 7C). Upon sacrifice of the animals, we 
confirmed elimination of the MS1PSMA endothelial cells via flow cytometry (data not 
shown). Together, these data demonstrate that destruction of the vasculature does indeed 
result in tumor cell loss.
Finally, we sought to determine whether bystander killing of adjacent ID8VEGF tumor cells 
could explain the reduction in tumor signal we observed in this model. We performed an in 
vitro killing assay in which we co-cultured MS1PSMA endothelial cells overnight at 
increasing ratios with ID8VEGF tumor cells and T cells. MS1PSMA cells were eliminated by 
the P28BBζ CAR T cells, but the ID8VEGF cells were unaffected by these T cells (Fig. 7D). 
These data suggest that tumor regression in vivo occurred through indirect loss of tumor 
cells, related to the disruption of the vasculature, rather than a direct bystander effect.
Discussion
Recent clinical trials have demonstrated the efficacy of CAR T cell-based immunotherapy 
for individuals with advanced cancer. Remarkable responses have been reported, for 
example, in patients receiving CD19-specific CAR T-cell therapy for the treatment of acute 
lymphocytic leukemia (38–40). In addition, active remission has been reported in patients 
with neuroblastoma after treatment with CAR T cells directed against the ganglioside, GD2 
(41). A critical component to the clinical success of these adoptive CAR T-cell therapies is 
the choice of target antigen. Ideally the antigen should be immunogenic, related to 
oncogenesis, and selectively expressed on the tumor tissue. One such tumor vascular marker 
is PSMA whose widespread distribution on vessels of many cancers makes it an ideal target 
for T cell-mediated vascular disruption. Here we have shown that T cells bearing a CAR 
against PSMA can destroy the tumor vasculature and elicit tumor regression. Importantly, 
our data also demonstrate that T cells can act as potent mediators of vascular disruption, 
thereby justifying the continued pursuit of this therapeutic approach.
One major advantage of using CAR T cells to disrupt the tumor vasculature, as opposed to 
conventional VDAs, is their ability to self-replicate and to persist long-term in patients (38). 
In addition, CAR T cells can trigger epitope spreading and help to reprogram the tumor 
microenvironment (42). Given the persistence and efficacy of CAR T cells, a second critical 
component to the clinical success of CAR T-cell therapy is safety. This cannot be 
overstated, as unexpected CAR cross-reactivity with healthy tissues has, unfortunately, 
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resulted in patient deaths (43). Prior to this study, tumor blood vessels destruction had been 
demonstrated successfully using CAR T cells engineered to recognize VEGFR-1 and 
VEGFR-2 (11) or VEGFR-2 alone (10). Although encouraging, VEGF receptors are also 
expressed by normal endothelial cells throughout the body and thus represent a significant 
risk for “on-target/off-tumor” toxicity. In contrast, PSMA has not been found on normal 
blood vessels. Nevertheless, it has been detected by immunohistochemistry in the prostate, 
kidney, liver, intestine, and colon, as well as on astrocytes of the brain (30,44,45). 
Discrepancies exist between these studies, however, and interpretation of the data is 
complicated by the existence of splice variants (12,13), localization of protein on the cell 
surface (apical versus basal), process of tissue collection, method of fixation, and the 
antibodies used to detect PSMA. Recognition of PSMA by our CAR T cells is mediated 
through the well-characterized scFv, J591. Encouragingly, imaging studies performed with 
radiolabeled J591 did not show accumulation of the mAb in either the kidneys or the small 
intestine (46). Furthermore, a phase 1 clinical trial with the J591 mAb demonstrated positive 
localization of the antibody to tumors with PSMA+ vasculature (47). Overall, this evidence 
suggests that J591-based CAR T cells will have a favorable safety profile in patients. Still, 
given the catastrophic potential of eliciting “on-target/off-tumor” toxicity, we propose that 
the creation of split-signaling CAR T cells could augment the safety of our current anti-
PSMA T cells. Using this system, T cells could be engineered to express two CARs, one 
providing signal 1 (CD3ζ) and the second providing signal 2 (i.e. CD28 and/or 4-1BB), such 
that each recognizes a unique tumor vascular antigen. The feasibility of this approach was 
previously demonstrated by Lanitis and colleagues (22), who showed that split-signaling 
CAR T cells are only fully activated when both CARs are engaged. Additional tumor 
endothelial targets have been identified in ovarian cancer (4, 48) as well as other tumors 
(49), enabling such combinatorial designs.
PSMA expression has been reported on the vasculature of nearly every solid tumor type 
examined (Supplementary Fig. 3A). This suggests that its presence may be critical to the 
formation of new blood vessels within the tumor. Here we found that 85% of women with 
ovarian cancer expressed PSMA on their tumor vasculature but only 40–60% of the CD31+ 
tumor endothelial cells were PSMA+. The presence of PSMA on the tumor vasculature may 
be partially explained by the increased metabolic needs of the activated tumor endothelium 
and may reflect a requirement for increased folate uptake. Functionally, PSMA hydrolyzes 
the gamma-glutamyl tail of folate polyglutamates, allowing cells to take up the resulting 
folates readily. At physiological folate concentrations the overexpression of PSMA was 
shown to confer growth advantage to tumor cells and enhance their invasive activity, 
potentially suggesting a similar role for the protein on the tumor endothelium (15). In 
addition, a direct role for PSMA in angiogenesis has been described, as the process was 
severely impaired in PSMA-null mice. In these mice the enzymatic activity of PSMA was 
required for endothelial cell invasion in vitro through regulation of integrin signaling, 
potentially explaining this phenotype (16). Therefore, we have hypothesized that PSMA-
expressing endothelial cells are critical for neovascular formation, and that their persistent 
immune-mediated elimination by CAR T cells both disrupts the existing vasculature and 
prevents the formation of new blood vessels. These inquiries provide further rationale for 
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the development of anti-PSMA CAR T-cell therapy targeting the tumor vasculature, and are 
actively being addressed within our lab.
In our MS1PSMA/ID8VEGF tumor model, we showed that adoptively transferred P28BBζ 
CAR T cells were able to persistently suppress nearly the entire PSMA-expressing fraction 
of the tumor endothelium. Their elimination, however, did not result in complete tumor 
regression. This could be because only a fraction of the tumor endothelial cells expressed 
PSMA within this model, similar to the human tumor specimens we analyzed. One method 
to overcome this obstacle would be to combine our anti-PSMA CAR T cells with additional 
treatment modalities. Conventional VDAs have been combined with both radiotherapy and 
chemotherapy for improved tumor control (50), suggesting that a similar approach could 
also augment the efficacy T cell-mediated vascular disruption. In addition, VDAs have also 
been successfully administered with anti-angiogenic agents as a means to target the existing 
tumor blood vessels, as well as impair the growth of new vessels (51). This has already been 
demonstrated using 1st generation CAR T cells directed against the VEGF receptors, and 
these T cells were found to synergize with anti-angiogenic therapy (11). Another approach 
to increase the efficacy of our anti-PSMA CAR T cells would be to combine them with 
CAR T cells or TCR-engineered T cells that recognize a second tumor endothelial antigen or 
the tumor itself. Steven Rosenberg and colleagues have illustrated this approach by showing 
that B16 tumors could be successfully eradicated in mice when anti-VEGFR-2 CAR T cells 
were combined with tumor-targeting T cells, but not when the mice were treated with the 
anti-vascular CAR T cells alone (52). Building on this observation, we also posit that 
patients whose tumor expresses PSMA on both the endothelium and tumor, as was observed 
here for one subject with ovarian cancer and has been noted in a number of cancers (30), 
may respond more successfully to treatment with our anti-PSMA T cells. We continue to 
pursue the answer to this question within our lab.
In conclusion, we have demonstrated that 3rd generation CAR T cells can target and 
eliminate PSMA-expressing endothelial cells of the tumor vasculature both in vitro and in 
vivo, and that elimination of these cells can result in tumor regression. We propose that split-
signaling may enhance their safety profile, and that, in combination with other treatments 
such as chemotherapy, radiation, and/or tumor cell-targeting T cells, they will provide 
important clinical benefit to patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Design and characterization of an anti-vascular CAR
(A) Lentiviral cassette design for the J591-based CAR constructs: Pζ, P28ζ, PBBζ, P28BBζ 
and the FR28BBζ specificity control. (B) Schematic representation of the P28BBζ CAR. (C) 
Representative transduction efficiencies, as measured by eGFP reporter, for the CAR 
constructs in primary human T cells. Closed histograms depict untransduced cells; open 
histograms depict transduced T cells. (D) Human PSMA expression on the HMEC-1 and the 
engineered HMEC-1PSMA endothelial cell lines. PSMA was detected by humanized J591 Ab 
(open histogram) and compared with human IgG control (closed histogram). (E) Overlay of 
histograms comparing the proliferative capacity of the T-cell groups 5 days after co-culture 
with HMEC-1PSMA. (F) Quantitative comparison of proliferation between CAR constructs 
harboring different signaling domains. The geometric mean fluorescence intensity of 
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Cellvue® Claret staining was measured for the CAR-positive T cells after 5 days in co-
culture with either HMEC-1 or HMEC-1PSMA (E:T = 2:1). To normalize across multiple 
donors, the MFI of CellVue® staining on CAR+ T cells after co-culture with HMEC-1PSMA 
was divided by the MFI of the CAR+ T cells after co-culture with the HMEC-1. *P < 0.05; 
data are means ±SEM from three independent donors. (G) Cytolytic activity of the various T 
cells after 18 h co-culture with HMEC-1 or HMEC-1PSMA. Lysis was measured via 
luciferase assay (specific lysis = 100 – (luciferase signal treated/luciferase signal untreated × 
100)). Data are means ±SD from triplicate cultures.
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Figure 2. PSMA is expressed on the vasculature of primary and metastatic cancer.<
br>(A) Representative staining for PSMA (top row), as well as PSMA and the endothelial 
marker, CD34 (bottom row). Sequential sections were cut and stained for either PSMA 
alone, or PSMA with CD34. Images in each column depict the same region within the same 
core. Original magnification, 200×; scale bar, 50 μm. (B) A heat map showing the presence 
or absence of PSMA on the vasculature of tumors taken from subjects with resected ovarian 
cancer (n = 15). (C) Representative tumor core staining for both PSMA (red) and CD34 
(brown). Black arrows indicate CD34+ vessels that are negative for PSMA expression; red 
arrows indicate dual-positive (CD34+PSMA+) vessels. (D) Level of PSMA expression on 
tumor endothelial cells (CD45−CD31+) from three subjects with gynecologic cancer. Tumor 
endothelial cells were collected by CD45 depletion followed by CD31 enrichment. PSMA 
was detected by humanized J591 Ab (open histogram) and compared with human IgG 
control (closed histogram). (E) The percentage of PSMA-positive CD45−CD31+ endothelial 
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cells remaining after overnight co-culture with CAR T cells (E:T = 1:1). Percentage = 
treated/untreated × 100. (F) IFNγ production by P28BBζ T cells after co-culture with CD31 
enriched or depleted targets (E:T = 1:1). Culture supernatants were collected at 18 h and 
IFNγ was measured by ELISA.
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Figure 3. P28BBζ CAR T cells target human tumor vasculature expressing PSMA.<
br>(A) Antigen-specific destruction of HMEC-1PSMA microvessels after 48 h co-culture 
with P28BBζ T cells. HMEC-1 or HMEC-1PSMA endothelial cells (RFP, red) were seeded 
atop a Matrigel basement membrane and allowed to form microvessels for 8 h prior to co-
culture with CAR-bearing T cells (eGFP, green) (E:T = 3:1). Images were taken at 0, 24, 
and 48 h. Original magnification, 40×; scale bar, 1 mm. (B) Immunofluorescence images of 
the HMEC-1PSMA endothelial cells at initiation (0 h) and termination (48 h) of co-culture 
with the P28BBζ T cells. Original magnification, 100×; scale bar, 500 μm. (C) Experimental 
design for the HMEC-1 pilot study. Mice were injected s.c. on each flank with 1.0×106 
HMEC-1 (left flank) and 1.0×106 HMEC-1PSMA (right flank) endothelial cells. T cells were 
administered concurrently via i.v. injection. Treated mice received 5.0×106 CAR-positive T 
cells. (D) Representative dot plots from treated or control mice showing human CD45 and 
CAR (eGFP) expression. Matrigel plugs were retrieved upon sacrifice (11 d) and were 
digested to yield a single-cell suspension. Cells were subsequently stained for human CD45 
and analyzed for eGFP expression using a flow cytometer. (E) CAR T cells as a percentage 
of the cells isolated from the Matrigel plugs. *P = 0.001, as determined by two-tailed 
Student’s t test. n = 2 mice in the FR28BBζ and P28BBζ; n = 1 mouse in the untreated 
(PBS) group. Data are means ±SEM. (F) CAR T cells as a percentage of total splenocytes. 
Spleens were isolated from mice upon sacrifice, mechanically disrupted, and analyzed for 
the presence of CAR T cells (eGFP). *P = 0.009, as determined by two-tailed Student’s t 
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test. n = 2 mice in the FR28BBζ and P28BBζ; n = 1 mouse in the untreated (PBS) group. 
Data are means ±SEM.
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Figure 4. P28BBζ CAR T cells eliminate PSMA+ vascular neoplasms.<
br>(A) Human PSMA expression on native (top row) and engineered (bottom row) murine 
endothelial cell lines. PSMA was detected by humanized J591 Ab (open histogram) and 
compared with human IgG control (closed histogram). (B) IFNγ production by P28BBζ T 
cells after co-culture with endothelial targets (E:T = 3:1). Culture supernatants were 
collected at 18 h and IFNγ was measured by ELISA. Representative donor shown; data are 
means ±SD of triplicate cultures. (C) Cytolytic activity of P28BBζ T cells after 18 h co-
culture with endothelial cell targets. Cell lysis measured by chromium release. 
Representative donor shown; data are means ±SD of triplicate cultures. (D) Tumor injection 
schematic and experimental design for the MS1 hemangioma study. Mice were injected s.c. 
on each flank with 1.0×107 MS1 (left flank) and 1.0×107 MS1PSMA (right flank) endothelial 
cells. Hemangiomas were allowed to develop for 24 days prior to i.v. injection of T cells. 
(E) Tumor progression, as measured by luciferase luminescence, in mice receiving PBS, 
FR28BBζ, or P28BBζ T cells. Mice were given a single injection of 5.0×106 CAR-positive 
T cells (arrows) 24 days after inoculation with tumor. n = 5 mice per group; data are means 
±SEM. *P < 0.05, as determined by two-tailed Student’s t test, for the P28BBζ treated group 
when compared to the FR28BBζ control group at the indicated time points. (F) 
Representative hemangiomas at the time of sacrifice (day 53). (G) Experimental design for 
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the H5V hemangiosarcoma tumor study. Mice were injected i.v. with 5.0×105 H5VPSMA 
endothelial cells. Lung tumors were allowed to engraft for 3 weeks prior to administration of 
T cells. (H) Tumor progression, as measured by luciferase luminescence, in mice receiving 
PBS, FR28BBζ, or P28BBζ T cells. Mice were given three injections of 5.0×106 CAR-
positive T cells beginning 21 days after tumor inoculation (arrows). n = 5 mice per group; 
data are means ±SEM. *P < 0.05, as determined by two-tailed Student’s t test, for the 
P28BBζ treated group when compared to the FR28BBζ control group at the indicated time 
points. (I) Survival curve for mice with H5VPSMA tumors. P28BBζ treated mice were 
sacrificed on day 108. P = 0.002, as determined by log-ranked (Mantel-Cox) test. n = 5 mice 
per group. (J) Tumor luminescence in representative mice before (day 20) and after T cell 
treatment (day 45).
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Figure 5. The MS1/ID8VEGF tumor model closely mimics normal tumor physiology.<
br>(A) Tumor injection schematic and experimental design for the MS1/ID8VEGF 
characterization study. Mice were given a single s.c. injection of 1.0×106 ID8VEGF tumor 
cells either alone or with 1.5×107 MS1 or 1.5×107 MS1PSMA endothelial cells and 
monitored for 41 days. (B) Representative staining for CD31 (green) and PSMA (blue) from 
an MS1PSMA/ID8VEGF tumor (d 41). Original magnification, 200×; scale bar, 100 μm. (C) 
The percentage of MS1PSMA-derived endothelial cells (CD31+) in ID8 tumors at time of 
sacrifice. PSMA was detected by humanized J591 Ab. *P < 0.0001, as determined by two-
tailed Student’s t test. n = 4 mice per group; data are means ±SEM. (D) The portion of 
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CD31+ endothelial cells present in tumor digests reported as a percentage of the total 
number of live cells collected. n = 4 mice per group; data are means ±SEM. (E) Tumor 
progression in mice harboring ID8VEGF, MS1/ID8VEGF, or MS1PSMA/ID8VEGF tumors. 
Tumor volumes were calculated via caliper measurement. n = 4 mice per group; data are 
means ±SEM. (F) Representative images taken from the same mouse on day 17 and 41 
showing eGFP radiance and firefly luminescence. (G,H) Correlation of endothelial cell 
signal (firefly luciferase, luminescence) with tumor signal (eGFP, radiant efficiency). Linear 
regression analysis was performed and the slope of best fit is shown (solid lines) for 
individual mice with either MS1/ID8VEGF (f) or MS1PSMA/ID8VEGF (g) tumors. (I,J) 
Statistical analysis describing the correlation of luminescence and radiant efficiency in mice 
with MS1/ID8VEGF (h) and MS1PSMA/ID8VEGF (i) tumors. Measurements were made 17–
41 days after tumor inoculation. Luciferase and radiant efficiency measurements were 
plotted against one another (n = 7) and Pearson correlation coefficients were calculated for 
each mouse (r). Statistical significance was evaluated by two-tailed test (P).
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Figure 6. CAR T cells ablate PSMA+ vasculature in solid tumors<
br>(A) Experimental design for the MS1/ID8VEGF tumor study. 6.7×105 ID8VEGF tumor 
cells were mixed with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right flank) 
endothelial cells and injected s.c. on the opposite flanks of each mouse. Tumors were 
allowed to engraft for 25 days before treatment with CAR T cells. (B) The persistence of the 
MS1 and MS1PSMA endothelial cells after treatment with PBS, FR28BBζ, or P28BBζ T 
cells. Mice were given three injections of 5.0×106 CAR-positive T cells beginning 25 days 
after tumor inoculation (arrows). The presence (or absence) of the MS1 and MS1PSMA 
endothelial cells was monitored via luciferase luminescence. n = 5 mice per group; data are 
means ±SEM. *P < 0.05, as determined by two-tailed Student’s t test, for the P28BBζ 
treated group when compared to the FR28BBζ control group at the indicated time points. 
(C) The percentage of PSMA positive tumor endothelial cells (CD45−CD31+) remaining 
after T cell administration to mice harboring MS1/ID8VEGF and MS1PSMA/ID8VEGF tumors. 
PSMA was detected by humanized J591 Ab. *P < 0.0001, as determined by two-tailed 
Student’s t test. n = 5 mice in the PBS and FR28BBζ groups; n = 2 mice in P28BBζ group. 
Data are means ±SEM. (D) The total percentage of tumor endothelial cells (CD45−CD31+) 
remaining in the MS1PSMA/ID8VEGF tumors after T cell administration. n = 5 mice in the 
PBS and FR28BBζ groups; n = 2 mice in P28BBζ group. Data are means ±SEM.
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Figure 7. CAR T cells induce secondary loss of tumor cells and regression of solid tumors.<
br>(A) Experimental design for the MS1/ID8VEGF tumor study. 6.7×105 ID8VEGF tumor 
cells were mixed with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right flank) 
endothelial cells and injected s.c. on opposite flanks of the same mice. Tumors were allowed 
to engraft for 22 days before T cell administration. (B) Tumor progression in mice receiving 
PBS, FR28BBζ, or P28BBζ T cells. Mice were given three injections of 5.0×106 CAR-
positive T cells beginning 22 days after tumor inoculation (arrows). The impact of T cell 
administration on the ID8VEGF tumor cells was measured via luciferase luminescence (left 
column) and tumor volumes were calculated using caliper measurements (right column). n = 
5 mice per group; data are means ±SEM. *P < 0.05, as determined by two-tailed Student’s t 
test, for the P28BBζ treated group when compared to the FR28BBζ control group at the 
indicated time points. (C) The fold-change in ID8VEGF tumor cell luminescence from the 
MS1/ID8VEGF and MS1PSMA/ID8VEGF tumors in mice receiving P28BBζ T cells. 
Luminescence measurements were normalized to those made prior to treatment (day 21). P 
values were determined by two-tailed Student’s t test and reflect the statistical significance 
of changes between day 24 and day 28. n = 5. (D) P28BBζ T cells do not elicit bystander 
killing of ID8VEGF when cultured in the presence of MS1PSMA. MS1PSMA cells were 
titrated into wells with ID8VEGF tumor cells and T cells at the described ratios and were 
cultured for 18 h. Lysis was measured via luciferase assay (specific lysis = 100 – (luciferase 
signal treated/luciferase signal untreated × 100)). Data are means ±SD from triplicate 
cultures.
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